| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1317888 | Journal of Inorganic Biochemistry | 2011 | 8 Pages |
Results from an investigation in an in vivo model of STZ-induced diabetic rats demonstrate that compound bis(1,2-dimethyl-3-hydroxy-4(1H)-pyridinonate)zinc(II), Zn(dmpp)2, significantly lowers the blood glucose levels of individuals, thus showing evidence of glucose lowering activity.The compound was selected from a set of eight zinc(II) complexes of 3-hydroxy-4-pyridinones with diverse lipophilicity that were prepared and characterized in our laboratory. Assessment of insulin-like activity of the complexes was firstly performed in vitro by measuring the inhibition of FFA release in isolated rat adipocytes. The results indicate that compounds bis(2-methyl-3-hydroxy-4-pyridinonate)zinc(II), Zn(mpp)2 and Zn(dmpp)2 display significantly higher activity than that of the respective positive control thus suggesting its selection for in vivo tests.Safety evaluation of the active zinc(II) compounds was performed in freshly isolated rat hepatocytes. The results support that cell viability is not significantly different from the control set after 1 and 2 h of incubation with both zinc(II) complexes.
Graphical abstractThis study is the first evaluation of the potential glucose lowering effect of 3-hydroxy-4-pyridinone-zinc(II) complexes in type I-like diabetic animals and the results demonstrate that compound Zn(dmpp)2 is a promising candidate to be further explored as a glucose lowering agent in the treatment of type I DM.Figure optionsDownload full-size imageDownload as PowerPoint slide
